Fentanyl
- Generic Name
- Fentanyl
- Brand Names
- Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N2O
- CAS Number
- 437-38-7
- Unique Ingredient Identifier
- UF599785JZ
- Background
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.
Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.
Fentanyl was FDA approved in 1968.
- Indication
Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.
Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.
- Associated Conditions
- Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain
- Associated Therapies
- Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy
A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy
- Conditions
- Chronic Pain
- First Posted Date
- 2006-01-02
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 53
- Registration Number
- NCT00271414
Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer
- Conditions
- PainCancer
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Alza Corporation, DE, USA
- Target Recruit Count
- 32
- Registration Number
- NCT00269763
Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer
- Conditions
- PainCancer
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Alza Corporation, DE, USA
- Target Recruit Count
- 7
- Registration Number
- NCT00269737
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 139
- Registration Number
- NCT00263575
- Locations
- 🇺🇸
Carolinas Pain Institute, Winston-Salem, North Carolina, United States
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
- Conditions
- PainCancer
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Registration Number
- NCT00262678
- Locations
- 🇺🇸
Carolinas Pain Institute, Winston-Salem, North Carolina, United States
Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil Based Anesthesia?
- Conditions
- Pain, Postoperative
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-07-06
- Lead Sponsor
- Ullevaal University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00241332
- Locations
- 🇳🇴
Ullevaal University Hospital, Oslo, Norway
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
- Conditions
- PainCancerSickle Cell AnemiaSevere Burns
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Registration Number
- NCT00236093
- Locations
- 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Childrens National Medical Center, Washington, District of Columbia, United States
🇺🇸Sacred Heart Medical Center, Spokane, Washington, United States
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
- Conditions
- Breakthrough Pain
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Cephalon
- Registration Number
- NCT00236145
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
- Conditions
- CancerBreakthrough Pain
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 38
- Registration Number
- NCT00236041
- Locations
- 🇺🇸
Tod Children's Hospital, Youngstown, Ohio, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Scottish Rite Children's Medical Center, Atlanta, Georgia, United States
Duragesic® (Fentanyl Transdermal System) Functionality Trial in Chronic Low Back Pain
- Conditions
- Low Back Pain
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- PriCara, Unit of Ortho-McNeil, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT00237341
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.